XOMA Royalty Reports $50M Cash Receipts, 68% Royalty Growth and $16M Buyback
XOMA Royalty generated $50.5 million in 2025 cash receipts—$33.6 million from royalties (up 68%) and $16.9 million in milestone payments—lifting total receipts 9%. The company repurchased 648,048 shares for $16 million, added 22 assets to its portfolio and closed seven acquisitions securing $11.7 million capital.
1. Financial Results
XOMA Royalty recorded $50.5 million in cash receipts for the full year 2025, comprising $33.6 million in royalties (up 68% year-over-year) and $16.9 million in milestone payments, lifting total receipts by 9% compared to 2024.
2. Portfolio Expansion and Share Buyback
During 2025, the company repurchased and retired 648,048 common shares for $16 million, added 22 new assets—including five programs in Phase 2 or Phase 3 development—to its royalty portfolio, and completed seven acquisitions that yielded $11.7 million in non-dilutive capital and economic interests in up to $1.1 billion of potential milestones.
3. 2026 Pipeline Catalysts
XOMA Royalty anticipates multiple catalysts in 2026, including Phase 2b volixibat data in primary sclerosing cholangitis in Q2, Phase 3 tumor HI results for ersodetug in H2, potential EMA decisions on OJEMDA and MIPLYFFA marketing applications, and regulatory updates for ersodetug in congenital HI and seralutinib in PAH.